IPPF’s response to the COVID-19 pandemic Good practices for delivering sexual and reproductive health and rights in a pandemic Click here to read the report Executive Summary All around the world, the COVID-19 pandemic has, and continues tochange the way...
In this Case Study series, we share progress, learning and innovation that has occurred within MAs over the course of the pandemic. To see full article visit: https://www.ippf.org/covid-19-ippf-innovation-and-best-practice The case studies are anchored in five key thematic areas: telemedicine for...
By Mahua Sen, Senior Adviser, Health Information Systems and Dr Heidi Gagnebe-Marriott, Director, Organizational Learning and Evaluation, members of the COVID-19 Taskforce. During the global crisis resulting from COVID-19, IPPF’s priority has been to minimize the disruption and ensure the continuity of sexual...
Here is the latest round-up of SRHR content related to our Member Associations and beyond. COVID-19: Pregnancy Q&A We’ve just published a piece answering some questions people may have about how COVID-19 may impact a pregnancy. A pregnancy during COVID-19...
IPPF EN and EPF launch report on Sexual and Reproductive Health and Rights in Europe during the Covid-19 pandemic This report has been compiled by IPPF EN and EPF from surveys that were conducted with their respective stakeholders on the...
Download full pdf (1.4mb) WHAT WE KNOW SO FAR Key messages for IPPF Member Associations Gender equality—the concept that all individuals should be treated in a way that ensures equal opportunities and outcomes—is a human right. The highest attainable standard...
Download full pdf (1.4mb) Recommendations for IPPF Member Associations Sexual and gender-based violence (SGBV) is a human rights violation and a public health issue that encompasses physical, sexual, economic, and psychological violence, including threats, coercion, child and early forced marriage,...
Download Full Pdf 0.1mb This statement was prepared by the International Medical Advisory Panel (IMAP) and was approved in April 2020. Background The novel coronavirus was first identified in December 2019 in Wuhan City, China and coronavirus disease (COVID‑19) declared...